News Briefing channel feed

Mesoblast gets a $110M life­line from Surg­Cen­ter De­vel­op­ment; uniQure still un­sure if gene ther­a­py spurred can­cer event

5 years ago

Mer­ck gets a PDU­FA date for its chron­ic cough con­tender; Mor­phic shares sky­rock­et on the heels of PhI da­ta roll­out in IBD

5 years ago

Gos­samer push­es ahead with failed asth­ma drug; Cull­gen gets $50M Se­ries B for pro­tein de­graders

5 years ago

Xen­cor, UCLA to part­ner for new ther­a­peu­tic an­ti­bod­ies; Schrödinger ex­pands part­ner­ship with Google Cloud

5 years ago

Ku­ra tees up its lead drug with a 'break­through' at the FDA; NCI teams up with Cy­brexa on pep­tide drug con­ju­gate

5 years ago

UCB builds on re­la­tion­ship with Mi­crosoft with new AI deal; Sanofi part­ners with Ger­man AAV vec­tor biotech

5 years ago

Am­gen lines up ex­pan­sion to Ote­zla's $13B fran­chise; Chi­na OKs 'break­through' use of PD-1

5 years ago

In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

5 years ago

Proven­tion Bio inks Chi­na deal for au­toim­mune pro­gram; Ky­owa Kirin re­leas­es pos­i­tive topline da­ta in atopic der­mati­tis

5 years ago

Pfiz­er chips in on $26M raise for rheuma­toid arthri­tis col­lab­o­ra­tor; Han­soh li­cens­es an an­ti-fun­gal for a mys­te­ri­ous in­fec­tion

5 years ago

Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic launch plans

5 years ago

Mys­tery in­vestors back a new NASH ap­proach; GSK an­tibi­otics sale trig­gers lay­off fears

5 years ago

Ex­sci­en­tia to col­lab­o­rate with Ox­ford's Alzheimer's cen­ter; Dana-Far­ber en­lists Reper­toire for head and neck can­cer

5 years ago

Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics

5 years ago

J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter en­roll­ment strug­gles

5 years ago

Jasper's cell ther­a­py con­di­tion­ing agent shows promise in small study; Vi­iV's Ruko­bia sees ap­proval in Eu­rope

5 years ago

Ra­mona Se­queira to be­come PhRMA's first fe­male chair; McK­in­sey reach­es near­ly $574 mil­lion set­tle­ment over in­volve­ment in opi­oid cri­sis

5 years ago

Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

5 years ago

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

5 years ago

Con­cert crushed on PhII schiz­o­phre­nia flop; Am­gen's so­tora­sib gets BTD in Chi­na

5 years ago

Cataba­sis Phar­ma­ceu­ti­cals snaps up HAE an­ti­body in buy­out; Glad­stone, UCSF sci­en­tist spear­head launch of neu­ro re­search cen­ter

5 years ago

Glax­o­SmithK­line moves malar­ia vac­cine pro­duc­tion to In­dia; Nevakar bags Eu­ro­pean part­ner and nine-fig­ure deal

5 years ago

Bomb squad called to As­traZeneca vac­cine plant; Lu­men nabs CARB-X award for low-cost an­tidiar­rheal

5 years ago

News brief­ing: Nestlé whips up re­search col­lab­o­ra­tion with new­ly-un­veiled Flag­ship up­start; Mar­i­anne De Backer joins Kro­nos board

5 years ago
First page Previous page 33343536373839 Next page Last page
A service from the Financial Times